Stanford Type A Aortic Dissection Can Be Treated with Endoprosthesis

Original title: Endovascular Repair of Ascending Aortic Dissection. A Novel Treatment Option for Patients Judged Unfit for Direct Surgical Repair. Reference: Qingsheng Lu, et al. J Am Coll Cardiol 2013;61:1917–24.

The dissecting aneurysm Type A represents 60% or aortic dissections and a real challenge as regards both therapeutics and the adequate moment to perform it, due to the serious complications this pathology entails. This analysis included 41 patients admitted between 2009 and 2011 with aortic dissection type A; all of them received endovascular treatment due to high surgical risk. Exclusion criteria included:

No patient presented death or any other complication at hospital level, except for two that presented arrhythmias. Hospital stay was 3.3±1 days. Follow up was 26 months (16-35); intervention was repeated in one case only; no patient presented severe aortic insufficiency or death. Complete thrombosis of ascending aorta false lumen was noted in all 15 patients and descending aorta false lumen thrombosis was seen in 10 patients. There were no changes in ejection fraction or in left ventricle end-diastolic diameter; a significant reduction of proximal and distal aorta diameter was observed, and a significant increase in true lumen.

Conclusion: 

The endovascular treatment of the Ascending Aorta Type A was the appropriate option for patients considered poor candidates for conventional surgery.

Commentary: 

Being able to solve this pathology by endoprosthesis implantation, with good outcomes, encourages us to use this strategy in patients that are no candidates for surgery. An analysis made by Dr. Sobocinski in the year 2011 had concluded that half of patients could be treated with this technique, which invites us to investigate further and motivates us to develop new, more efficient devices, to cover a larger number of patients. 

Courtesy of Dr. Carlos Fava
Interventional cardiologist.
Favaloro Foundation Argentina.

Dr. Carlos Fava.

More articles by this author

Supera vs. Eluvia at 3 Years in Severely Calcified Femoropopliteal Lesions

Severe calcification remains one of the main predictors of restenosis and the need for repeat revascularization following endovascular treatment of femoropopliteal disease. In this...

Is abdominal aortic aneurysm screening cost-effective in women?

Although ultrasound screening for abdominal aortic aneurysm (AAA) is a well-established strategy in men over 65 years of age, its value in women remains...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

Supera vs. Eluvia at 3 Years in Severely Calcified Femoropopliteal Lesions

Severe calcification remains one of the main predictors of restenosis and the need for repeat revascularization following endovascular treatment of femoropopliteal disease. In this...

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...